In clinical practice, early and accurate diagnoses enable appropriate, data driven and targeted management decisions. In many cases molecular diagnostics have supplanted traditional methods as the most accurate method.
In particular, nucleic acid tests display remarkable sensitivity and specificity in the detection and characterization of infectious agents. The characterization of the genome allows optimization of patient management in fields as diverse as infection and cancer.
Specific genotypes of both infectious organisms and human cancers are increasingly understood to be associated with disease progression and outcome, or susceptibility to particular chemotherapeutic agents.
The detection of infectious diseases at an early stage is critical not only for directing infection control and public health interventions.Our group aims to develop assays that are clinically valuable for the detection and management of infections and cancers using proprietary PCR-based techniques.
Our expertise is in the development and application of nucleic acid probe technology to diagnose and monitor human diseases. Currently, we develop molecular diagnostic applications for several analytical platforms. These include real-time PCR cyclers, the Luminex® xMAP analyzer and pyrosequencing gene analyzers.
Stratagene Mx3005P and Mx3000P QPCR Systems, Bio-Rad CFX96™ Real-Time PCR Detection System, Qiagen Rotor-Gene Q 5plex HRM System, Applied Biosystems 7500 Fast Real-Time PCR System, Qiagen PyroMark Q96 ID, Hitachi Small DNA Analyzer.